Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Inclusion Criteria:

• Advanced gastric cancer (including GEJ) that has progressed following first-linetherapy.
• Patients must be ≥18 years of age. Age ≥20 if Japanese
• Provision of tumour sample (from either a resection or biopsy).
• At least one lesion (measurable and/or non-measurable) that can be accurately assessedby imaging (CT/MRI) at baseline and following up visits.

Exclusion Criteria:

• More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapywith more than 6 month wash out period) for the treatment of gastric cancer in theadvanced setting.
• Any previous treatment with a Polyadenosine 5'-diphosphoribose [poly-(ADP-ribose)]polymerisation (PARP) inhibitor, including olaparib.
• Patients with second primary cancer, except: adequately treated non-melanoma skincancer, curatively treated in-situ cancer of the cervix, or other solid tumourscuratively treated with no evidence of disease for ≥5 years.
• Human Epidermalgrowth Factor Receptor-2 (HER2) positive patients.